Nalaganje...
DABIGATRAN AND IDARUZIZUMAB. NEW OPPORTUNITIES FOR IMPROVING PATIENT SAFETY
The widespread use of new oral anticoagulants in clinical practice requires improving the safety of medication use, i.e. the use of specific reversal agents, if necessary. Idarucizumab, a humanied monoclonal antibody fragment, is the first reversal agent authorized in our country that binds to dabig...
Shranjeno v:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Jezik: | Russo |
| Izdano: |
«REMEDIUM GROUP» Ltd.
2019-06-01
|
| Serija: | Атеротромбоз |
| Teme: | |
| Online dostop: | https://www.aterotromboz.ru/jour/article/view/183 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|